Drug Profile
Research programme: angiopoietin modulators - Regeneron
Alternative Names: Angiopoeitin-like 4 antibody - Regeneron; ANGPTL4 - RegeneronLatest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Developer Regeneron Pharmaceuticals; University of California at San Francisco
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inducing agents; Angiogenesis inhibitors; Angiopoietin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Inflammation; Metabolic disorders
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for preclinical development in Metabolic-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA